α-methylacyl coenzyme A racemase, Ki-67, and topoisomerase IIα in cystoprostatectomies with incidental prostate cancer

American Journal of Clinical Pathology

Volumn 128, Issue 4, 2007, Pages 657-664

  Santinelli, Alfredo ^a   Mazzucchelli, Roberta ^a   Barbisan, Francesca ^a   Lopez Beltran, Antonio ^b   Cheng, Liang ^c   Scarpelli, Marina ^a   Montironi, Rodolfo ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^c INDIANA UNIVERSITY   (United States)

Author keywords

methylacyl coenzyme A racemase; Cell proliferation; Cystoprostatectomy; High grade prostatic intraepithelial neoplasia; Incidental cancer; Indolent cancer; Insignificant cancer; Ki 67; Prostate cancer; Significant cancer; Topoisomerase II

Indexed keywords

2 METHYLACYL COENZYME A RACEMASE; DNA TOPOISOMERASE (ATP HYDROLYSING); KI 67 ANTIGEN;

ARTICLE; ATROPHY; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTECTOMY; EPITHELIUM; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATECTOMY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN EXPRESSION;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; ATROPHY; CELL COUNT; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; HUMANS; INCIDENTAL FINDINGS; KI-67 ANTIGEN; MALE; MIDDLE AGED; PROSTATE; PROSTATECTOMY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; RACEMASES AND EPIMERASES; TUMOR MARKERS, BIOLOGICAL;

EID: 35348859538     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/P065G467FKKUJDE5     Document Type: Article

References (20)

1. Montironi R, Mazzucchelli R, Santinelli A, et al. Incidentally detected prostate cancer in cystoprostatectomies: pathological and morphometric comparison with clinically detected cancer in totally embedded specimens. Hum Pathol. 2005;36:646-654.
2. Sakr WA, Grignon DJ, Crissman JD, et al. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo. 1994;8:439-443.
3. Stamey TA, Freiha FS, McNeal JE, et al. Localized prostate cancer: relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer. 1993;71:933-938.
4. Troncoso P, Babaian RJ, Ro JY, et al. Prostatic intraepithelial neoplasia and invasive prostatic adenocarcinoma in cystoprostatectomy specimens. Urology. 1989;34:52-56.
5. Lapointe J, Li C, Higgins JP, et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci U S A. 2004;101:811-816.
6. Kumar-Sinha C, Chinnaiyan AM. Molecular markers to identify patients at risk for recurrence after primary treatment for prostate cancer. Urology. 2003;62:19-35.
7. Takahashi S, Suzuki S, Takahashi S, et al. Differences between latent and clinical prostate carcinomas: lower cell proliferation activity in latent cases. Prostate. 2006;66:211-217.
8. Ananthanarayanan V, Deaton RJ, Yang XJ, et al. Alteration of proliferation and apoptotic markers in normal and premalignant tissue associated with prostate cancer. BMC Cancer. 2006;17:6-73.
9. Xu J, Stolk JA, Zhang X, et al. Identification of differentially expressed genes in human prostate cancer using subtraction and microarray. Cancer Res. 2000;60:1677-1682.
10. Adley BP, Yang XJ. Application of alpha-methylacyl coenzyme A racemase immunohistochemistry in the diagnosis of prostate cancer: a review. Anal Quant Cytol Histol. 2006;28:1-13.
11. Beach R, Gown AM, De Peralta-Venturina MN, et al. P504S immunohistochemical detection in 405 prostatic specimens including 376 18-gauge needle biopsies. Am J Surg Pathol. 2002;26:1588-1596.
12. Jiang Z, Woda BA, Rock KL, et al. P504S: a new molecular marker for the detection of prostate carcinoma. Am J Surg Pathol. 2001;25:1397-1404.
13. Zhou M, Chinnaiyan AM, Kleer CG, et al. alpha-Methylacyl-CoA racemase: a novel tumor marker over-expressed in several human cancers and their precursor lesions. Am J Surg Pathol. 2002;26:926-931.
14. Jiang Z, Wu CL, Woda BA, et al. P504S/alpha-methylacyl-CoA racemase: a useful marker for diagnosis of small foci of prostatic carcinoma on needle biopsy. Am J Surg Pathol. 2002;26:1169-1174.
15. Yang XJ, Wu CL, Woda BA, et al. Expression of alpha-methylacyl-CoA racemase (P504S) in atypical adenomatous hyperplasia of the prostate. Am J Surg Pathol. 2002;26:921-925.
16. Helpap B. The significance of the P504S expression pattern of high-grade prostatic intraepithelial neoplasia (HGPIN) with and without adenocarcinoma of the prostate in biopsy and radical prostatectomy specimens. Virchows Arch. 2006;448:480-484.
17. De Marzo AM, Meeker AK, Zha S, et al. Human prostate cancer precursors and pathobiology. Urology. 2003;62:55-62.
18. De Marzo AM, Platz EA, Epstein JI, et al. A working group classification of focal prostate atrophy lesions. Am J Surg Pathol. 2006;30:1281-1291.
19. Montironi R, Mazzucchelli R, Barbisan F, et al. HER2 expression and gene amplification in pT2a Gleason score 6 prostate cancer incidentally detected in cystoprostatectomies: comparison with clinically detected androgen-dependent and androgen-independent cancer. Hum Pathol. 2006;37:1137-1144.
20. Montironi R, Mazzucchelli R, Barbisan F, et al. Immunohistochemical expression of endothelin-1 and endothelin-A and endothelin-B receptors in high-grade prostatic intraepithelial neoplasia and prostate cancer. Eur Urol. 2007. doi:10.1016/J.eururo.2007.02.24.